CTIS2023-504602-11-00招募中1 期
Effects of Dopaminergic Therapy in Patients with Alzheimer's Disease: A 24 weeks prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate Alzheimer's disease patients. - DOPAD-3
Fondazione Santa Lucia IRCCS0 个研究点目标入组 348 人开始时间: 2023年5月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 348
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Men and women (non-childbearing potential, as defined in Appendix 2) with a diagnosis of AD according to IWG criteria 2. Age 50-85 years 3. MRI or computerized tomography (CT) assessment within twelve months before baseline, corroborating the clinical diagnosis of AD and excluding other potential causes of dementia, especially cerebrovascular lesions (see exclusion criteria, number 3) 4. Patients who show CSF biomarker data supporting the diagnosis of AD measured within the last 3 years, or patients with a positive Amyloid Pet Scan within the last 3 years will qualify for the study 5. Mild to moderate stage of AD according to MMSE =18 and =26 6. Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild) 7. Evidence of frontal lobe dysfunctions as assessed by FAB =14 8. Absence of major depressive disease according to GDS of < 5 9. Formal education for eight or more years 10. Previous decline in cognition for more than six months as documented in patient medical records 11. A caregiver available and living in the same household or interacting with the patient and available if necessary to assure administration of drug 12. Patients living at home or nursing home setting without continuous nursing care 13. General health status acceptable for a participation in a 6-month clinical trial 14. Stable pharmacological treatment of any other chronic condition for at least one month prior to screening 15. No regular intake of prohibited medications. 16. Signed informed consent by the patient, prior to the initiation of any study specific procedure and signed consent of the caregiver
排除标准
- •1. Failure to perform screening or baseline examinations 2. Hospitalization or change of chronic concomitant medication one month prior to screening or during screening period 3. Clinical, laboratory or neuro-imaging findings consistent with: • other primary degenerative dementia (dementia with Lewy bodies, fronto-temporal dementia, Huntington’s disease, Creutzfeldt-Jakob Disease, Down’s syndrome, etc.); • other neurodegenerative condition (Parkinson’s disease, amyotrophic lateral sclerosis, etc.); • orthostatic hypotension and autonomic disorders • cerebrovascular disease (major infarct, one strategic or multiple lacunar infarcts, extensive white matter lesions > one quarter of the total white matter); • other central nervous system diseases (severe head trauma, tumors, subdural hematoma or other space occupying processes, etc.); • seizure disorder; • other infectious, metabolic, or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.). 4. A current DSM-V diagnosis of active major depression, schizophrenia, or bipolar disorder 5. Clinically significant, advanced, or unstable disease that may interfere with primary or secondary variable evaluations, and which may bias the assessment of the clinical or mental status of the patient or put the patient at special risk, such as: • chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, Gamma GT, alkaline phosphatase > 2.5 ULN); • respiratory insufficiency; • renal insufficiency (serum creatinine >2 mg/dl) or creatinine clearance = 30 mL/min according to Cockcroft-Gault formula). In case of creatinine clearance =30 mL/min, an alternative verification of the renal function must be completed using Cystatin C analysis. In case of normal level of Cystatin C, the patient can be included; • heart disease (myocardial infarction, unstable angina, heart failure, Cardiomyopathy within six months before screening); • bradycardia (heart beat <50/min.) or tachycardia (heart beat >95/min); • hypertension (>180/95) or hypotension (<90/60) requiring treatment with more than three drugs; •AV block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcB-interval (males >450 and females >470 msec); • uncontrolled diabetes defined by HbA1c >8.5;
研究者
相似试验
已完成
不适用
The dopaminergic system in patients with functional dyspepsia analyzed by an alpha-methyl-para-tyrosine (AMPT) challenge test and single photon emission computed tomography (SPECT) imaging before and after treatment with amitriptylineDyspepsiaFunctional dyspepsia (FD)Digestive SystemISRCTN63226989Academic Medical Center (AMC), Department of Gastroenterology (The Netherlands)60
招募中
Unknown
Does levodopa/carbidopa, a common Parkinson's Disease drug, affect stomach emptying, blood pressure and heart rate?Postprandial hypotensionDelayed gastric emptyingOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemMetabolic and Endocrine - Other metabolic disordersNeurological - Parkinson's diseaseCardiovascular - Other cardiovascular diseasesParkinson's diseaseACTRN12624001010583Professor Karen Jones, The University of Adelaide20
已完成
2 期
The effect of bromocriptine on endometrioma sizeIRCT20140802018655N6Shiraz University of Medical Sciences60
进行中（未招募）
1 期
Dopaminergic therapy for Alzheimer's disease patientsMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersAlzheimer's diseaseEUCTR2015-002965-43-ITI.R.C.C.S. FONDAZIONE S.LUCIA130
已完成
不适用
The effects of increased levels of dopamine on the activation in the dopaminergic system.n.v.t.10009841NL-OMON33408niversiteit Maastricht20